Skip to main content
Erschienen in: Virchows Archiv 2/2014

01.02.2014 | Original Article

Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder

verfasst von: Heejeong Lee, Sun-Young Jun, Youn-Soo Lee, Hee Jin Lee, Weon Sun Lee, Chul Soo Park

Erschienen in: Virchows Archiv | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Histopathological grading of papillary urothelial tumors (PUTs) of the urinary bladder is subjective and poorly reproducible. We investigated the relationship between the expression of frequently deregulated microRNAs (miRNAs) as well as their target genes (ZEB1/ZEB2) and bladder cancer histopathological grade in an attempt to find a miRNA that might allow more reliable grading of PUTs. We measured the expression levels of four miRNAs (miR-145, miR-205, miR-125b, and miR-200c) in 120 formalin-fixed, paraffin-embedded bladder tumor tissue samples using real-time PCR assays. ZEB1 and ZEB2 expression was assessed in the same bladder tissues by immunohistochemistry. MiR-205 distinguished low-grade papillary urothelial carcinoma (LG) from high-grade papillary urothelial carcinoma (HG), and miR-145 distinguished HG from infiltrating carcinoma (CA) with an area under the receiver operator characteristic curve (AUC) of 0.992 and 0.997, respectively (sensitivity/specificity of 95.8/96.7 % and 100/91.7 %, respectively; p < 0.05). The expression level of miR-125b was significantly lower in LG than in PUNLMP, with an AUC value of 0.870 (93.3 % sensitivity and 84.2 % specificity; p < 0.05). ZEB1 immunoreactivity was more frequently detected in HG than in LG (57 % vs 13 %, p < 0.01) and in HG than in CA (57 % vs 17 %, p < 0.01). ZEB2 immunoreactivity was more frequent in CA than in HG (83 % vs 54 %, p < 0.05). ZEB1/ZEB2 and miRNAs expression seems to reliably distinguish between different grades of PUTs of the urinary bladder. They might well serve as useful complementary diagnostic biomarkers for grading of papillary urothelial tumors.
Literatur
1.
Zurück zum Zitat Chen YB, Tu JJ, Kao J, Zhou XK, Chen YT (2008) Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. Arch Pathol Lab Med 132:224–231PubMed Chen YB, Tu JJ, Kao J, Zhou XK, Chen YT (2008) Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. Arch Pathol Lab Med 132:224–231PubMed
2.
Zurück zum Zitat van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boeve ER, Jobsis AC, van der Kwast TH (2010) The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 57:1052–1057PubMedCrossRef van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boeve ER, Jobsis AC, van der Kwast TH (2010) The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 57:1052–1057PubMedCrossRef
3.
Zurück zum Zitat May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S (2010) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 57:850–858PubMedCrossRef May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, Gunia S (2010) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 57:850–858PubMedCrossRef
4.
Zurück zum Zitat Shim JW, Ro JY, Cho NH, Kim YS, Park YW, Shim SI, Lee DW, Choi YJ, Han WS (2006) ISUP/WHO classification of papillary urothelial neoplasms of urinary bladder: consensus study conducted by Korean Society of Urogenital Pathology. Korean J Pathol 40:282–288 Shim JW, Ro JY, Cho NH, Kim YS, Park YW, Shim SI, Lee DW, Choi YJ, Han WS (2006) ISUP/WHO classification of papillary urothelial neoplasms of urinary bladder: consensus study conducted by Korean Society of Urogenital Pathology. Korean J Pathol 40:282–288
5.
Zurück zum Zitat Yorukoglu K, Tuna B, Dikicioglu E, Duzcan E, Isisag A, Sen S, Mungan U, Kirkali Z (2003) Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 443:734–740PubMedCrossRef Yorukoglu K, Tuna B, Dikicioglu E, Duzcan E, Isisag A, Sen S, Mungan U, Kirkali Z (2003) Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 443:734–740PubMedCrossRef
6.
Zurück zum Zitat MacLennan GT, Kirkali Z, Cheng L (2007) Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51:889–897, discussion 897-898PubMedCrossRef MacLennan GT, Kirkali Z, Cheng L (2007) Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51:889–897, discussion 897-898PubMedCrossRef
7.
Zurück zum Zitat Shim JW, Cho KS, Choi YD, Park YW, Lee DW, Han WS, Shim SI, Kim HJ, Cho NH (2008) Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch 452:353–362PubMedCentralPubMedCrossRef Shim JW, Cho KS, Choi YD, Park YW, Lee DW, Han WS, Shim SI, Kim HJ, Cho NH (2008) Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch 452:353–362PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112:55–59PubMedCrossRef Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112:55–59PubMedCrossRef
10.
Zurück zum Zitat Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48–57PubMedCrossRef Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48–57PubMedCrossRef
11.
Zurück zum Zitat Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69:8472–8481PubMedCentralPubMedCrossRef Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69:8472–8481PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Mansson W, Rovira C, Hoglund M (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124:2236–2242PubMedCrossRef Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Mansson W, Rovira C, Hoglund M (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124:2236–2242PubMedCrossRef
13.
Zurück zum Zitat Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, Summerhayes IC (2010) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 28:39–48PubMedCrossRef Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, Summerhayes IC (2010) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 28:39–48PubMedCrossRef
14.
Zurück zum Zitat Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060–5072PubMedCrossRef Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060–5072PubMedCrossRef
15.
Zurück zum Zitat Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128:1327–1334PubMedCrossRef Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128:1327–1334PubMedCrossRef
16.
Zurück zum Zitat Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G: a robust methodology to study urine microRNA as tumor marker (2010) microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661CrossRef Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G: a robust methodology to study urine microRNA as tumor marker (2010) microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661CrossRef
17.
Zurück zum Zitat Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392PubMedCrossRef Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392PubMedCrossRef
18.
Zurück zum Zitat Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhoi BP, Kjems J, Borre M, Orntoft TF (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860PubMedCrossRef Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhoi BP, Kjems J, Borre M, Orntoft TF (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860PubMedCrossRef
19.
Zurück zum Zitat Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125:345–352PubMedCrossRef Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125:345–352PubMedCrossRef
20.
Zurück zum Zitat Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T (2011) MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 128:1758–1769PubMedCrossRef Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T (2011) MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 128:1758–1769PubMedCrossRef
21.
Zurück zum Zitat Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, Orntoft TF (2010) miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29:1073–1084PubMedCrossRef Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, Orntoft TF (2010) miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29:1073–1084PubMedCrossRef
22.
Zurück zum Zitat Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180:1808–1815PubMedCrossRef Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180:1808–1815PubMedCrossRef
23.
Zurück zum Zitat Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA, Summerhayes IC (2011) A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 29:794–801PubMedCrossRef Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA, Summerhayes IC (2011) A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 29:794–801PubMedCrossRef
24.
Zurück zum Zitat Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC (2011) Novel ZEB1 expression in bladder tumorigenesis. BJU Int 107:656–663PubMedCrossRef Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC (2011) Novel ZEB1 expression in bladder tumorigenesis. BJU Int 107:656–663PubMedCrossRef
25.
Zurück zum Zitat Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741PubMedCrossRef Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741PubMedCrossRef
26.
Zurück zum Zitat Catto JW, Alcaraz A, Bjartell AS, DeVere WR, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681PubMedCrossRef Catto JW, Alcaraz A, Bjartell AS, DeVere WR, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681PubMedCrossRef
27.
Zurück zum Zitat Eble J, Sauter G, Epstein J, Sesterhenn I (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC, Lyon, France, pp 89–158 Eble J, Sauter G, Epstein J, Sesterhenn I (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC, Lyon, France, pp 89–158
28.
Zurück zum Zitat Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22:894–907PubMedCentralPubMedCrossRef Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22:894–907PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Oztas E, Avci ME, Ozcan A, Sayan AE, Tulchinsky E, Yagci T (2010) Novel monoclonal antibodies detect Smad-interacting protein 1 (SIP1) in the cytoplasm of human cells from multiple tumor tissue arrays. Exp Mol Pathol 89:182–189PubMedCrossRef Oztas E, Avci ME, Ozcan A, Sayan AE, Tulchinsky E, Yagci T (2010) Novel monoclonal antibodies detect Smad-interacting protein 1 (SIP1) in the cytoplasm of human cells from multiple tumor tissue arrays. Exp Mol Pathol 89:182–189PubMedCrossRef
Metadaten
Titel
Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder
verfasst von
Heejeong Lee
Sun-Young Jun
Youn-Soo Lee
Hee Jin Lee
Weon Sun Lee
Chul Soo Park
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 2/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1518-x

Weitere Artikel der Ausgabe 2/2014

Virchows Archiv 2/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …